Varaico: Literature-Extracted Genetic Variants

Gene:KRAS
Variant:p.V14L
Back to variants list

KRAS

NM_004985.5:p.V14L

Associated Papers

Molecular analysis of lung adenocarcinomas from the SAFIR02-Lung cohort reveals new metastasis-associated copy-number alterations including frequent mutant-specific KRAS-allelic imbalance and identifies CDKN2A homozygous deletions as an independent biomarker of poor prognosis.

Hamza A et al.

British Journal of Cancer, 2025

40931129 (PubMed )
Supplement: 41416_2025_3183_MOESM4_ESM.xlsx › S4B_Amino-acid_substitions

Leveraging genomic diagnostics for prognostics and therapeutics in pediatric acute leukemia.

Newman H et al.

Hemasphere, 2025

41306327 (PubMed )
Supplement: HEM3-9-e70269-s013.xlsx › Supplemental_Table_5_-_SSVs

Clinico-hematopathologic and Genetic Characteristics of Korean Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm: A Retrospective Single-center Cohort Study.

Kim J et al.

Annals of Laboratory Medicine, 2025

41093602 (PubMed )
Supplement: ALM3679_Supple0.xlsx › S6

Coevolution of Atypical BRAF and KRAS Mutations in Colorectal Tumorigenesis.

Woolley CE et al.

Molecular Cancer Research : Mcr, 2025

Comprehensive structure-function analysis reveals gain- and loss-of-function mechanisms impacting oncogenic KRAS activity.

Kwon JJ et al.

Biorxiv : the Preprint Server for Biology, 2024

39484452 (PubMed )
Supplement: media-2.zip › Extended_Data_Tables › Extended_Data_Table_1.xlsx › KRAS_GOF_DMS_Screen

Clonal Dynamics and Relapse Risk Revealed by High-Sensitivity FLT3-Internal Tandem Duplication Detection in Acute Myeloid Leukemia.

Oduro KA et al.

Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2024

The Pan-RAF-MEK Nondegrading Molecular Glue NST-628 Is a Potent and Brain-Penetrant Inhibitor of the RAS-MAPK Pathway with Activity across Diverse RAS- and RAF-Driven Cancers.

Ryan MB et al.

Cancer Discovery, 2024

38588399 (PubMed )
Supplement: cd-24-0139_supplementary_table_6_suppst6.xlsx › OMNI

A High Percentage of NSCLC With Germline CHEK2 Mutation Harbors Actionable Driver Alterations: Survey of a Cancer Genomic Database and Review of Literature.

Zhang SS et al.

Jto Clinical and Research Reports, 2022

Massively parallel phenotyping of coding variants in cancer with Perturb-seq.

Ursu O et al.

Nature Biotechnology, 2022

Circulating tumor DNA mutation profile is associated with the prognosis and treatment response of Chinese patients with newly diagnosed diffuse large B-cell lymphoma.

Guan T et al.

Frontiers in Oncology, 2022

36465410 (PubMed )
Supplement: DataSheet_1.xlsx › Supplementary_table_3

Multiclonal complexity of pediatric acute lymphoblastic leukemia and the prognostic relevance of subclonal mutations

Antić Ž et al.

Haematologica, 2021

33147938 (PubMed )
Supplement: 2020_259226_ANTIC_SUPPL_TABLES.xlsx › Supplementary_Table_3

Frequency and coexistence of KRAS, NRAS, BRAF and PIK3CA mutations and occurrence of MMR deficiency in Danish colorectal cancer patients.

Poulsen TS et al.

Apmis : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica, 2021

KRAS mutations in brown tumor of the jaws in hyperparathyroidism.

Guimarães LM et al.

Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, 2020

Kasumi leukemia cell lines: characterization of tumor genomes with ethnic origin and scales of genomic alterations.

Kasai F et al.

Human Cell, 2020

32180206 (PubMed )
Supplement: 13577_2020_347_MOESM1_ESM.pdf

KRAS mutations in implant-associated peripheral giant cell granuloma.

Martins-Chaves RR et al.

Oral Diseases, 2020

Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers.

Hao HX et al.

Molecular Cancer Therapeutics, 2019

31439712 (PubMed )
Supplement: 15357163mct190170-sup-217436_2_supp_5691166_pvrtk4.xlsx › PTPN11_shRNA_data

Demographic trends and KRAS/BRAFV600E mutations in colorectal cancer patients of South China: A single-site report.

Fu X et al.

International Journal of Cancer, 2019

NOTCH1 pathway activating mutations and clonal evolution in pediatric T-cell acute lymphoblastic leukemia.

Kimura S et al.

Cancer Science, 2019

30387229 (PubMed )
Supplement: CAS-110-784-s012.xlsx › Sup3_Mutation

New Challenges in Targeting Signaling Pathways in Acute Lymphoblastic Leukemia by NGS Approaches: An Update.

Montaño A et al.

Cancers, 2018

Integrated genomic analyses reveal frequent TERT aberrations in acral melanoma.

Liang WS et al.

Genome Research, 2017

Identification of a genetically defined ultra-high-risk group in relapsed pediatric T-lymphoblastic leukemia.

Richter-Pechańska P et al.

Blood Cancer Journal, 2017

28157215 (PubMed )
Supplement: bcj20173x11.xlsx › SNVsInDelsCalled_in214Pts

LowMACA: exploiting protein family analysis for the identification of rare driver mutations in cancer.

Melloni GE et al.

Bmc Bioinformatics, 2016

26860319 (PubMed )
Supplement: 12859_2016_935_MOESM2_ESM.xlsx › Table_S5

Prognostic signature and clonality pattern of recurrently mutated genes in inactive chronic lymphocytic leukemia.

Hurtado AM et al.

Blood Cancer Journal, 2015

26314984 (PubMed )
Supplement: bcj201565x1.xls › Hoja1

Acquired initiating mutations in early hematopoietic cells of CLL patients.

Damm F et al.

Cancer Discovery, 2014

24920063 (PubMed )
Supplement: 21598290cd140104-sup-tab1.xls › CLL12
Select a paper to view details
UCSC Genome Browser·Imprint·Privacy·Terms·Feedback·Email Updates·

Regarding the variants extracted from papers and shown text snippets from research papers, the following holds: "Some rights reserved. This work permits non-commercial use, distribution and reproduction in any medium, provided the original author and source are credited."